Barclays PLC lowered its holdings in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 91.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,942 shares of the company's stock after selling 125,931 shares during the quarter. Barclays PLC's holdings in Ginkgo Bioworks were worth $98,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Algert Global LLC bought a new stake in shares of Ginkgo Bioworks in the second quarter worth about $36,000. Wellington Wealth Strategies LLC. purchased a new position in Ginkgo Bioworks during the 2nd quarter valued at approximately $41,000. Thoroughbred Financial Services LLC bought a new stake in Ginkgo Bioworks in the 2nd quarter worth approximately $70,000. Benjamin F. Edwards & Company Inc. raised its holdings in shares of Ginkgo Bioworks by 1,606.9% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 234,836 shares of the company's stock worth $79,000 after acquiring an additional 221,078 shares in the last quarter. Finally, Mackenzie Financial Corp bought a new position in shares of Ginkgo Bioworks during the 2nd quarter valued at approximately $251,000. Institutional investors own 78.63% of the company's stock.
Analysts Set New Price Targets
Separately, TD Cowen boosted their price target on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a "buy" rating in a research report on Friday, September 20th. Three analysts have rated the stock with a sell rating, one has given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $4.58.
Check Out Our Latest Report on DNA
Ginkgo Bioworks Trading Down 1.1 %
Shares of Ginkgo Bioworks stock traded down $0.12 on Thursday, reaching $11.08. The company had a trading volume of 1,420,835 shares, compared to its average volume of 1,486,107. The firm has a market capitalization of $636.87 million, a price-to-earnings ratio of -0.85 and a beta of 1.09. The firm's 50-day simple moving average is $9.05. Ginkgo Bioworks Holdings, Inc. has a 1 year low of $5.26 and a 1 year high of $64.40.
Ginkgo Bioworks Company Profile
(
Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Featured Stories
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
